Mr. Besselaar is the founder of Princeton Investment Advisors, Inc. (PIA) and serves as the company's current President and Chief Investment Officer. He is also an officer of Omnivest (Bermuda) Ltd., an investment holding company based in Bermuda. During Mr. Besselaar's tenure at PIA, Omnivest has invested in many highly successful investment partnerships, with investment mandates that have focused on distressed debt, convertible arbitrage, event driven transactions, long/short equity, private equity and buy-outs. Mr. Besselaar assisted in the representation of a 40% equity stake in PharmaNet, Inc., an international contract research organization and portfolio company of Omnivest, by serving as an active member of that company's Board of Directors from 1999 until its sale to a strategic buyer in 2004 for approximately $250 million. Mr. Besselaar also served as a General Partner of River Capital Partners, Ltd., a multi-manager fund geared towards high-net worth offshore investors. Mr. Besselaar has a bachelor of arts degree in international relations from the University of Richmond and a master's degree in real estate development and finance from Columbia University.
Mr. Davidson is a Managing Director of H.I.G. Ventures and focuses on investment opportunities in the life sciences sector. Prior to joining H.I.G., Mr. Davidson served as Vice President for Ventures West, with a focus on venture investing in life sciences companies. He began his career with Eli Lilly Company where he spent a decade in various management roles in the U.S. and Canada including business development, strategic planning, market research, and financial planning. After Lilly, he spent a year as the Vice-President of Corporate Business Development at SYN-X Pharma. Mr. Davidson's current board seats include Alder Biopharmaceuticals, Gemin X Biotechnologies Inc, HyperBranch Medical Technology, NeurAxon Inc., Novadaq Technologies, Inc. (public June 2005), Oncogenex Technologies Inc. and Tranzyme Pharma. In addition, Mr. Davidson served on the board of Salmedix, Inc. before it was acquired by Cephalon in June 2005. Mr. Davidson has a bachelor of commerce degree from McGill University and an MBA from Harvard Business School.
Mr. Day is a commercial development specialist, whose primary focus and expertise is the dermatology marketplace. He has held strategic sales, marketing, and management positions with major pharmaceutical companies, including Allergan Pharmaceuticals and Ferndale Laboratories. In 2000, Mr. Day founded Rx-Pharma Pharmaceuticals, Inc., a specialty pharmaceutical business with two licensed products ("Pandel" and "Pro-Q") and a delivery platform technology, "Restoraderm." After building a sales force and developing several products utilizing the Restoraderm platform, he successfully negotiated and consummated the sale of Rx-Pharma to CollaGenex Pharmaceuticals, Inc., assuming the position of Vice President, Dermatology at CollaGenex. A key to Mr. Day's success in the pharmaceutical industry is his strong ongoing relationships with the members of the dermatology community and capitalizing on their experience and expertise during the development, launch, and sales of new products. These ongoing working relationships are the basis for building invaluable Advisory Boards, and Steering Committees and aid tremendously in the successful launch of unique prescription drug products.
Dr. Gallagher has been a member of the Board of Directors of CollaGenex Pharmaceuticals, Inc., a specialty pharmaceutical company focused on providing innovative medical therapies for targeted disease classes in high-potential markets, such as the dental and dermatology markets, since 1994. Dr. Gallagher also served as President and Chief Executive Officer of CollaGenex from April 1994 until his retirement in December 2003, and as Chairman of the Board until December 2003. From 1988 until joining CollaGenex, Dr. Gallagher was employed by Bristol-Myers Squibb Company and its predecessor, Squibb Corporation, in various executive positions, including strategic planning, worldwide product and business development, and marketing. Dr. Gallagher was the vice president and general manager of Squibb Diagnostics, the in vivo imaging pharmaceutical division where he was responsible for drug development, including filing new drug applications with the U.S. Food and Drug Administration and other regulatory authorities worldwide. Prior to that, Dr. Gallagher served for 10 years with the EI DuPont de Nemours & Co. in a variety of pharmaceutical research, development, marketing, and business management positions.
Dr. Krochmal is a Board certified Dermatologist with 24+ years experience in the pharmaceutical and consumer goods industries focusing on the development of new products both locally and globally. His most recent role was as Executive Vice President, Research and Product Development for Connetics Corporation, a specialty dermatology company. Dr Krochmal began his career in the pharmaceutical industry following 8 years of private dermatology practice by joining Westwood Pharmaceuticals (the dermatology subsidiary of Bristol-Myers Squibb) in 1983 as Director of Clinical Research. Over the subsequent 10 years, he held several roles of increasing responsibility including VP, Dermatology Research and Development overseeing both preclinical and clinical disciplines, and VP, Worldwide Medical Development providing global support in Biostatistics & Data Management, Human Pharmacology, Drug Safety, Medical Communications and Clinical Study Field Operations to all five Therapeutic Areas of Bristol-Myers Squibb. In 1993, Dr Krochmal joined Unilever PLC, where he spent the next decade in various senior management positions directing the worldwide development of numerous consumer products for the Home and Personal Care Division. Dr Krochmal received his Bachelor of Medical Sciences degree from the University of Wisconsin, his Doctor of Medicine from the Medical College of Wisconsin, and his board certification in dermatology following successful completion of the residency training program at the University of Missouri Medical Center. In 2005, Dr. Krochmal was appointed to the Board of Directors of the International Academy of Cosmetic Dermatology. He is a fellow of the American Academy of Dermatology, a Diplomat of the American Board of Dermatology, and a member of the International Society of Dermatology and the Dermatology Foundation. During his career, Dr Krochmal played a pivotal role in the approval of 15 NDAs/ANDAs for new topical dermatologicals including LacHydrin®, Ultravate®, Dovonex®, Evoclin®, Verdeso®, Olux-E® and Extina®.
Mr. Zisson is a partner of Thomas, McNerney & Partners. He joined Thomas, McNerney in 2002 and is currently a board member of Clarus Therapeutics, Inc., Tranzyme Pharma, Inc. and Zogenix, Inc. Before joining the firm, he spent eleven years in the research department at Hambrecht & Quist (and its successor firms Chase H&Q and JPMorgan H&Q). During his tenure at H&Q, Mr. Zisson led research teams covering the biotechnology, specialty pharmaceutical, large-cap pharmaceutical, drug delivery and diagnostic industries. After the merger of Chase H&Q and JPMorgan, he became the firm's Health Care Strategist. Mr. Zisson was named twice in The Wall Street Journal's All-Star Analysts Survey, including during his last year at JPMorgan when he placed in all three categories: stock picking (#1 in pharmaceuticals), earnings estimate accuracy (tied for #2), and 'home run' hitting (#8 across all industries). He graduated magna cum laude from Brown University, where he was elected to Phi Beta Kappa.